AgomAb Therapeutics (NASDAQ:AGMB) Stock: Insider David Epstein Acquires 15,000 Shares

AgomAb Therapeutics NV (NASDAQ:AGMB) Director David Epstein acquired 15,000 shares of the firm’s stock in a transaction on Thursday, November 5th. The stock was bought at an average price of $6.90 per share, with a total value of $103,500.00. Following the purchase, the director directly owned 40,000 shares of the company’s stock, valued at $276,000. This represents a 60.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

AgomAb Therapeutics Stock Up 9.6%

Shares of AGMB stock opened at $7.64 on Friday. The stock’s 50-day moving average is $10.26 and its two-hundred day moving average is $11.86. AgomAb Therapeutics NV has a 1 year low of $6.46 and a 1 year high of $17.82.

AgomAb Therapeutics (NASDAQ:AGMB) last posted its earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share for the quarter. Research analysts forecast that AgomAb Therapeutics NV will post -1.77 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on AGMB shares. Piper Sandler initiated coverage on AgomAb Therapeutics in a research note on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 price objective for the company. B. Riley Financial began coverage on shares of AgomAb Therapeutics in a research report on Thursday, July 23rd. They set a “buy” rating and a $34.00 target price on the stock. Wall Street Zen cut shares of AgomAb Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, September 27th. Cantor Fitzgerald assumed coverage on shares of AgomAb Therapeutics in a research report on Wednesday, August 19th. They issued an “overweight” rating for the company. Finally, HC Wainwright reiterated a “buy” rating on shares of AgomAb Therapeutics in a research note on Wednesday, October 21st. Eight research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, AgomAb Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.50.

AgomAb Therapeutics Company Profile

Agomab Therapeutics N.V. is a clinical-stage biotechnology company focused on developing medicines that promote tissue regeneration and address diseases associated with fibrosis and tissue damage. The company’s research is centered on biological pathways involved in repair, remodeling and the disease microenvironment.

Agomab’s lead program is AGMB-129, an orally administered, gut-restricted small-molecule inhibitor of transforming growth factor beta receptor 1, also known as ALK5. The program is being developed for intestinal fibrosis associated with Crohn’s disease, a condition in which scar tissue can narrow the intestine and contribute to complications.

The company also maintains earlier-stage discovery and development programs intended to apply its regenerative medicine expertise to additional gastrointestinal and oncology-related indications.